Literature DB >> 6146795

Imaging of medullary thyroid cancer with 131I-MIBG.

K Endo, K Shiomi, K Kasagi, J Konishi, K Torizuka, K Nakao, H Tanimura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6146795     DOI： 10.1016/s0140-6736(84)90525-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

Review 1.  Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.

Authors:  Ioannis Ilias; Chaitanya Divgi; Karel Pacak
Journal:  Semin Nucl Med       Date:  2011-09       Impact factor: 4.446

2.  Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.

Authors:  P Gasparoni; D Rubello; G Ferlin
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

3.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

4.  Accumulation of thallium-201 in medullary thyroid cancer with negative serum calcitonin and carcinoembryonic antigens: a case report.

Authors:  M Koizumi; T Watari; K Hirabayashi
Journal:  Ann Nucl Med       Date:  1993-02       Impact factor: 2.668

5.  Localization of hepatic metastases by radiolabelled anti-carcinoembryonic antigen antibody and meta-iodobenzylguanidine in a patient with medullary thyroid carcinoma.

Authors:  K Liewendahl; M Välimäki; M Taavitsainen
Journal:  Eur J Nucl Med       Date:  1993-06

6.  Uptake of 131I-MIBG by medullary carcinoma of thyroid in familial cases.

Authors:  G Coutris; J N Talbot; G Kabla; C Calmettes; G Milhaud
Journal:  Eur J Nucl Med       Date:  1986

7.  [Malignant adrenal pheochromocytoma--problems in evaluating clinical diagnosis and morphologic extent].

Authors:  M Brückner; B C Padberg; M Dürig; S Schröder
Journal:  Langenbecks Arch Chir       Date:  1993

Review 8.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 9.  Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1994-06

10.  Scintigraphic detection of recurrence of medullary thyroid cancer.

Authors:  M Koizumi; Y Yamada; E Nomura; M Amano; Y Okajima; H Okizuka; K Yamada; S Sawano; T Kitahara; T Yamashita
Journal:  Ann Nucl Med       Date:  1995-05       Impact factor: 2.668
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.